Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 SAN DIEGO , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of
View HTML
Toggle Summary Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on September 10, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to four new employees and
View HTML
Toggle Summary Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
SAN  DIEGO (August 3, 2020) – Retrophin,  Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president  and chief  executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry.
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August: William Blair Biotech Focus Conference 2020 Date: Thursday, August 6, 2020 Time: 3:00 p.m.
View HTML
Toggle Summary Retrophin Reports Second Quarter 2020 Financial Results
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equivalents of $457 million following
View HTML
Toggle Summary Retrophin to Report Second Quarter 2020 Financial Results
SAN DIEGO , July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
SAN DIEGO , June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET .
View HTML
Toggle Summary Retrophin Announces Pricing of Public Offering of Common Stock
SAN DIEGO , June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin.
View HTML
Toggle Summary Retrophin Announces Proposed Public Offering of Common Stock
SAN DIEGO , June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin.
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference
SAN DIEGO , May 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET . A live webcast of the presentation will be
View HTML